Frontlight ResearchEarly access
Taking people in CzechiaPhase 4
Checking blood levels of heart failure medicines in chronic heart failure
Studies how blood levels of heart failure medicines relate to heart failure signs.
Key facts
- Who runs it
- Fakultni Nemocnice Ostrava
- Where
- Poruba, CzechiaSee the site
- Trial code
- Registry title
- Use of determination of drug levels to optimize pharmacotherapy of heart failure
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 9 Apr 2024
- Planned end
- 30 Apr 2026
- Type of study
- Interventional
- Record updated
- 12 March 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure with reduced ejection fraction who already take, or are starting, the listed heart medicines. It studies how blood levels of these medicines relate to signs of heart failure.
- Age
- Over 18 years
- Sex
- Women and men
- Disease stage
- Heart failure with reduced ejection fraction (HFrEF)
- Earlier treatment
- Already on, or newly starting, treatment with the listed medicines
Main reasons for not taking part
- Allergy to the medicine or any of its other ingredients
- Pregnant or breastfeeding women
- Unstable or decompensated heart failure (NYHA IV) needing intravenous heart-support drugs (for beta-blocker users)
- Very slow heartbeat (heart rate <50), 2nd or 3rd degree A-V block without a pacemaker, or cardiogenic shock (for beta-blocker users)
- Severe kidney or liver problems, or high potassium (>5.5 mmol/l) (for spironolactone or sacubitril/valsartan users)
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- HFrEF with already established or newly started treatment with the listed medicinal products
- Male and female patients over 18 years of age
- Signed Informed Consent with participation in the study
- Women of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) result at the initial visit and use an acceptable method of contraception with a home control urine pregnancy test every 3 months throughout the duration of the study
Who cannot take part
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - concurrent intravenous treatment with verapamil or diltiazem
- Additional exclusion criteria for patients using Sacubitril/Valsartan - concomitant use with ACE inhibitors
- Additional exclusion criteria for patients using Sacubitril/Valsartan - angioedema related to previous ACE inhibitor treatment or a history of ARB treatment
- Hypersensitivity to the medicinal substance or to any auxiliary substance
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - sinus node dysfunction syndrome (including sinoatrial block)
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - Prinzmetal angina
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - severe peripheral arterial circulation disorders
- Additional exclusion criteria for patients using Spironolactone - acute renal failure
- Additional exclusion criteria for patients using Spironolactone - severe renal impairment (estimated glomerular filtration rate <10 ml/min)
- Additional exclusion criteria for patients using Spironolactone - Addison's disease
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - Unstable or decompensated heart failure belonging to the NYHA IV group according to the New York Heart Association classification, requiring intravenous inotropic support
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - History of bronchospasm or asthma
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - Severe obstructive airways disease
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - severe bradycardia (heart rate <50)
- Additional exclusion criteria for patients using Spironolactone - hyperkalemia >5.5 mmol/l
- Additional exclusion criteria for patients using Spironolactone - hyponatremia <125 mmol/l
- Additional exclusion criteria for patients using Spironolactone - concurrent use of eplerenone or other potassium-sparing diuretics
- Additional exclusion criteria for patients using Sacubitril/Valsartan - concomitant use with medicinal products containing Aliskiren in patients with diabetes mellitus or in patients with impaired renal function (eGFR <60 ml/min/1.73 m2)
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - severe hypotension (systolic blood pressure <85 mmHg)
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - untreated pheochromocytoma
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - metabolic acidosis
- Additional exclusion criteria for patients using Spironolactone - anuria
- Pregnant and breastfeeding women
- Additional exclusion criteria for patients using Spironolactone - porphyria
- Additional exclusion criteria for patients using Sacubitril/Valsartan - hereditary or idiopathic angioedema
- Additional exclusion criteria for patients using Sacubitril/Valsartan - severe liver dysfunction, biliary cirrhosis and cholestasis
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - Clinically manifest liver dysfunction
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - 2nd and 3rd degree A-V block (unless a permanent pacemaker is implanted)
- Additional exclusion criteria for patients using Bisoprolol, Carvedilol, Metoprolol succinate or Nebivolol - cardiogenic shock
Where in Czechia
- Fakultni Nemocnice OstravaPoruba, CzechiaTaking people
About the trial
What the trial wants to find out
The primary objective of the CT is to determine whether and how the serum concentrations of the listed medicinal products, including their metabolites, correlate with selected clinical indicators of heart failure.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Use of determination of drug levels to optimize pharmacotherapy of heart failure
- Plain-language title
- Checking blood levels of heart failure medicines in chronic heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 March 2024